IL-4 inhibits superoxide production by human mononuclear phagocytes.
The activation of mononuclear phagocytes (M phi) and their generation of oxidative products is influenced by various cytokines as well as by normal maturational changes. We examined the effects of IL-4 on superoxide (O2-) production (cytochrome c reduction) by cultured M phi and the modulation of these effects by IFN-gamma and IL-1. Incubation of IL-4 (200 U/ml) with M phi inhibited M phi PMA (100 ng/ml)-stimulated O2-. production by 23% at 24 h, 34% at 48 h, and 70 to 85% at 72 to 96 h. IL-4 similarly inhibited M phi O2-. production in response to zymosan. IL-4 did not affect M phi viability, adherence to microtiter plates, or ability to phagocytose boiled yeast. In comparison with M phi, neutrophil O2-. production was not inhibited after 4 to 20 h incubation with IL-4. When IL-4 was washed out as early as 1 h after the initiation of M phi culture, significant inhibition of O2-. production was observed 4 days later. Sequential addition of either IL-4 or IFN-gamma to cultures demonstrated reciprocal cytokine effects on M phi; IL-4 partially inhibited O2-. production by M phi previously treated with rIFN-gamma whereas rIFN-gamma partially augmented O2-. production by M phi previously treated with IL-4. Because IL-4 has been reported to inhibit IL-1 production, add-back experiments were performed; addition of IL-1 only partly reconstituted O2-. production in IL-4-treated cells. Further characterization showed that although M phi protein synthesis was enhanced by both rIFN-gamma and IL-4 treatment, acid phosphatase, a marker of maturation to the macrophage phenotype, was markedly increased at an earlier time point in IL-4-treated M phi, and correlated with a decline in O2-. production. The ability of IL-4 to suppress M phi O2-. production implicates IL-4 as an important regulator of this aspect of the inflammatory response.
Abramson
S L
SL
Bacterial Diseases Section, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Gallin
J I
JI
D000135:Acid Phosphatase / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D006801:Humans; D007158:Immunologic Techniques; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism*; D008264:Macrophages / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D009000:Monocytes / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D010586:Phagocytes / Q000378:metabolism*; D013481:Superoxides / Q000378:metabolism*; D015054:Zymosan / Q000494:pharmacology
D007375:Interleukin-1; D013481:Superoxides; D015847:Interleukin-4; D007371:Interferon-gamma; D015054:Zymosan; D000135:Acid Phosphatase